1. Home
  2. CRBP vs ARAY Comparison

CRBP vs ARAY Comparison

Compare CRBP & ARAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Corbus Pharmaceuticals Holdings Inc.

CRBP

Corbus Pharmaceuticals Holdings Inc.

HOLD

Current Price

$8.38

Market Cap

134.8M

Sector

Health Care

ML Signal

HOLD

Logo Accuray Incorporated

ARAY

Accuray Incorporated

HOLD

Current Price

$0.56

Market Cap

68.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRBP
ARAY
Founded
2009
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
134.8M
68.6M
IPO Year
2014
2006

Fundamental Metrics

Financial Performance
Metric
CRBP
ARAY
Price
$8.38
$0.56
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
2
Target Price
$46.17
$3.50
AVG Volume (30 Days)
145.8K
1.1M
Earning Date
01-01-0001
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
64.31
87.50
EPS
N/A
N/A
Revenue
$4,822,272.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$220.00
$4.58
P/E Ratio
N/A
N/A
Revenue Growth
97.62
N/A
52 Week Low
$4.64
$0.50
52 Week High
$20.56
$2.10

Technical Indicators

Market Signals
Indicator
CRBP
ARAY
Relative Strength Index (RSI) 56.25 36.27
Support Level $8.39 $0.50
Resistance Level $8.43 $1.12
Average True Range (ATR) 0.48 0.05
MACD 0.13 0.01
Stochastic Oscillator 79.61 47.40

Price Performance

Historical Comparison
CRBP
ARAY

About CRBP Corbus Pharmaceuticals Holdings Inc.

Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

About ARAY Accuray Incorporated

Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, treatment solutions which set the standard of radiation therapy care with the objective of helping patients live lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention.

Share on Social Networks: